Biomunex Pharmaceuticals SAS
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Biomunex Pharmaceuticals SAS
Tapping into the interplay between gut microbiota and an underappreciated subset of T cells could lead to therapies in a range of diseases.
MD Anderson teams with Eisbach on precision oncology and with Yingli on a five-year translational research effort. Moffitt inks tie-ups with Dyve and Turnstone.
Plus deals involving Sanofi/SIRION, Merck KGAA/Day One, Beijing Tide/Graviton, Vaccinex/Surface Oncology, Athena/Tris, Biomunex/Onward, Cellectis/Cytovia
- Large Molecule
- Other Names / Subsidiaries
- Biomunex Pharmaceuticals Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.